Macrophage-Targeting by CSF1/1R Blockade in Pancreatic Cancers.

Abstract

Published in Cancer Research in 2014, Zhu and colleagues achieved a mechanistic leap in our understanding of cancer-associated macrophage biology with their proof-of-concept study showing that macrophage-specific targeting, via blocking colony-stimulating factor-1 (CSF1) signaling through its cognate receptor CSF1R, synergized with checkpoint immunotherapy to enhance antitumor immunity in mouse models of pancreatic cancer. Here, we reflect on the critical set of observations presented in this study and how the study's findings fueled the subsequent efforts to translate CSF1/1R-specific and other tumor-associated macrophage modulating therapies into the clinic.See related article by Zhu and colleagues, Cancer Res 2014;74:5057-69.

• Authors: Won Jin Ho, Elizabeth M Jaffee
• Journal: Cancer research (Cancer Res) Vol. 81 Issue 24 Pg. 6071-6073 (12 15 2021) ISSN: 1538-7445 [Electronic] United States
• PMID: 34911778 (Publication Type: Journal Article, Comment)
• Copyright: ©2021 American Association for Cancer Research.

Chemical References

• Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
• Macrophage Colony-Stimulating Factor
• Receptor, Macrophage Colony-Stimulating Factor

Topics

• Animals
• Immunotherapy
• Macrophage Colony-Stimulating Factor
• Macrophages
• Mice
• Pancreatic Neoplasms (drug therapy)
• Receptor, Macrophage Colony-Stimulating Factor
• Receptors, Granulocyte-Macrophage Colony-Stimulating Factor